Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Peptides can offer the versatility needed for a successful oncology drug discovery approach.
Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …

The efficacy of drugs widely varies in individuals, and the gut microbiota plays an important
role in this variability. The commensal microbiota living in the human gut encodes several …

Recent advances in materials science and engineering highlight the importance of
designing sophisticated biomaterials with well-defined architectures and tunable properties …

Antimicrobial peptides (AMPs) constitute a promising class of alternatives to antibiotics to
curb antimicrobial resistance. Nonetheless, their utility as a systemic agent is hampered by …

The development of antibody-drug conjugates (ADCs) has significantly been advanced in
the past decade given the improvement of payloads, linkers and conjugation methods. In …

A new nano-antibiotic was synthesized from the conjugation of multi-walled carbon
nanotubes with levofloxacin (MWCNT-LVX) through covalent grafting of drug with surface …

Biomedical research often focuses on properties that differentiate between diseased and
healthy tissue; one of the current focuses is elevated expression and altered localisation of …

The high selectivity and affinity of antibody binding have made antibodies all-pervasive tools
in therapy, diagnosis, and basic science. A plethora of chemogenetic approaches has been …